Snapshot
- AI co-pilots can solve specific biopharma use-cases efficiently.
- Co-pilots can assist in building and testing clinical trial protocols.
- They can target specific physicians treating at-risk patients.
- Flight Deck software democratizes AI, enabling self-service problem-solving.
Overview
Simon Arkell explores the role of AI co-pilots in the biopharma industry, underlining their potential to solve specific use-cases quickly and efficiently. Industry recognition of these co-pilots’ capabilities has grown, evidenced by OpenAI’s APIs enabling chat boxes within Excel for specific data inquiries.
For the biopharma industry, imagine having proprietary genomics data, patient data, and commercial targeting data within a secure data store that these AI platforms could access. These co-pilots could sit on the desktop, a click away, ready to answer questions and facilitate interactions. For example, they could assist in building and testing clinical trial protocols or targeting specific physicians treating patients at risk of disease progression.
Arkell’s company is developing a software called Flight Deck, allowing customers to benefit from the co-pilot metaphor. This software provides a drag-and-drop GUI interface, enabling users to pull in the required data and models. This self-service approach democratizes AI, making it accessible for solving specific problems at scale without the need for a dedicated development team or data science expertise.
